Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hatteras Venture Partners
Biotech
Music to its ears: Tune bags $40M to alter gene expression
The epigenome sparks investor interest again as Tune Therapeutics emerges with $40 million to bankroll meds that dial up, or down, gene expression.
Kyle LaHucik
Dec 2, 2021 6:00am
Vigil targets 'sentinel cells' to fight neurodegeneneration
Dec 8, 2020 8:00am
Hatteras raises $94M to invest in early-stage biotechs
Apr 15, 2019 7:30am
Chutes & Ladders—Ex-GSK CEO Witty joins venture capital
Sep 22, 2017 7:00am
Ex-GlaxoSmithKline CEO Witty joins Hatteras as venture partner
Sep 19, 2017 7:31am
Boston Scientific leads $23M round for heart failure startup
Apr 19, 2017 7:35am
